Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00846287 · ClinicalTrials.gov registry record · NA
Assessment of Arformoterol for Chronic Obstructive Pulmonary Disease (COPD) Using Hyperpolarized 3He MRI
A NA study, sponsored by University of Massachusetts, Worcester.
- Completed
- Registry status
- NA
- Development phase
- 16
- Enrollment target
NCT00846287 is a NA study that has completed, run by University of Massachusetts, Worcester. The registered enrollment target is 16 participants.
The verdict
NCT00846287, a NA study, has completed, sponsored by University of Massachusetts, Worcester.
- COMPLETED
- Registry status
- NA
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to determine efficacy of MR imaging with hyperpolarized helium-3 gas in COPD patients both before and after treatment.
Interventions
- DRUG Placebo
- DRUG Hyperpolarized Helium-3
- DRUG Aformoterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2008-11 |
| Est. Completion | 2011-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00846287
The ClinicalTrials.gov registry entry for NCT00846287 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Massachusetts, Worcester, which has 240 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00846287 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00846287 about?
NCT00846287 is a clinical study titled "Assessment of Arformoterol for Chronic Obstructive Pulmonary Disease (COPD) Using Hyperpolarized 3He MRI". The purpose of this study is to determine efficacy of MR imaging with hyperpolarized helium-3 gas in COPD patients both before and after treatment.
What is the current status of trial NCT00846287?
This trial is currently completed. It is a NA study. The enrollment target is 16 participants. The study started on 2008-11. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00846287?
The interventions under investigation include: Placebo (DRUG), Hyperpolarized Helium-3 (DRUG), Aformoterol (DRUG).
Who is sponsoring clinical trial NCT00846287?
This trial is sponsored by University of Massachusetts, Worcester, which has 240 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.